skip to main content
Idioma:
Refinado por: Nome da Publicação: Journal Of Thoracic Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Dziadziuszko, Rafal ; Mok, Tony ; Peters, Solange ; Han, Ji-Youn ; Alatorre-Alexander, Jorge ; Leighl, Natasha ; Sriuranpong, Virote ; Pérol, Maurice ; de Castro Junior, Gilberto ; Nadal, Ernest ; de Marinis, Filippo ; Frontera, Osvaldo Arén ; Tan, Daniel S.W. ; Lee, Dae Ho ; Kim, Hye Ryun ; Yan, Mark ; Riehl, Todd ; Schleifman, Erica ; Paul, Sarah M. ; Mocci, Simonetta ; Patel, Rajesh ; Assaf, Zoe June ; Shames, David S. ; Mathisen, Michael S. ; Gadgeel, Shirish M.

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2040-2050 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
2
EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Material Type:
Artigo 		Adicionar ao Meu Espaço

EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

Garon, E.B. ; Cho, B.C. ; Luft, A. ; Alatorre-Alexander, J. ; Geater, S.L. ; Kim, S.-W. ; Ursol, G. ; Hussein, M. ; Lim, F.L. ; Yang, C.-T. ; Araujo, L.H. ; Saito, H. ; Reinmuth, N. ; Kohlmann, M. ; Shi, X. ; Mann, H. ; Peters, S. ; Mok, T. ; Johnson, M.L.

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S349-S350 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
Material Type:
Artigo 		Adicionar ao Meu Espaço

P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)

Peled, N. ; Ponce, S. ; Alatorre-Alexander, J. ; Kinkolykh, A. ; Vicuna, B. ; Mathisen, M. ; Mocci, S. ; Paul, S. ; Schleifman, E. ; Dziadziuszko, R.

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S684-S684 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
Material Type:
Artigo 		Adicionar ao Meu Espaço

12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study

Reinmuth, N. ; Cho, B.C. ; Luft, A. ; Alexander, J.A. Alatorre ; Geater, S. Lucien ; Laktionov, K. ; Kim, S-W. ; Ursol, G. ; Hussein, M. ; Lim, F.L. ; Yang, C-T. ; Araujo, L.H. ; Saito, H. ; Barrett, K. ; Lowery, C. ; Tattersfield, R. ; Peters, S. ; Garon, E.B. ; Mok, T.S.K. ; Johnson, M.L.

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S44-S46 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

Peters, S. ; Cho, B.C. ; Luft, A. ; Alatorre-Alexander, J. ; Geater, S.L. ; Kim, S.-W. ; Ursol, G. ; Hussein, M. ; Lim, F.L. ; Yang, C.-T. ; Araujo, L.H. ; Saito, H. ; Reinmuth, N. ; Stewart, R. ; Lai, Z. ; Doake, R. ; Krug, L. ; Garon, E.B. ; Mok, T. ; Johnson, M.L.

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S39-S41 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

Johnson, M. ; Cho, B.C. ; Luft, A. ; Alatorre-Alexander, J. ; Geater, S.L. ; Laktionov, K. ; Vasiliev, A. ; Trukhin, D. ; Kim, S. ; Ursol, G. ; Hussein, M. ; Lim, F. ; Yang, C. ; Araujo, L. ; Saito, H. ; Reinmuth, N. ; Shi, X. ; Poole, L. ; Peters, S. ; Garon, E. ; Mok, T.

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S844-S844 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.